The Medical Letter on Drugs and Therapeutics
Drugs for Menopausal Symptoms
August 10, 2020 (Issue: 1604)The primary symptoms of menopause are genitourinary (genitourinary syndrome of menopause; GSM) and vasomotor (VMS). Vulvovaginal atrophy can cause vaginal burning, irritation and dryness, dyspareunia, and dysuria, and increase the risk of urinary...more
- A Stuenkel et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100:3975.
- The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017; 24:728.
- CJ Crandall et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause 2018; 25:11.
- Ospemifene (Osphena) for dyspareunia. Med Lett Drugs Ther 2013; 55:55.
- JA Simon et al. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013; 20:418.
- GD Constantine et al. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause 2015; 22:36.
- Addendum: Ospemifene (Osphena) for dyspareunia. Med Lett Drugs Ther 2013; 55:84.
- Prasterone (Intrarosa) for dyspareunia. Med Lett Drugs Ther 2017; 59:149.
- DL Barton et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Cancer Care 2018; 26:1335.
- AH MacLennan et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; 4:CD002978.
- RT Chlebowski et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA 2020; 324:369.
- JL Shifren et al. Menopausal hormone therapy. JAMA 2019; 321:2458.
- RH Cobin et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause-2017 update. Endocr Pract 2017; 23:869.
- Drugs for postmenopausal osteoporosis. Med Lett Drugs Ther 2020; 62:105.
- Conjugated estrogens/bazedoxifene (Duavee) for menopausal symptoms and prevention of osteoporosis. Med Lett Drugs Ther 2014; 56:33.
- N Santoro et al. Compounded bioidentical hormones in endocrinology practice: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2016; 101:1318.
- AM Gaudard et al. Bioidentical hormones for women with vasomotor symptoms. Cochrane Database Syst Rev 2016; 8:CD010407.
- DL Barton et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010; 28:3278.
- EW Freeman et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011; 305:267.
- DJ Portman et al. Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause. Menopuase 2014; 21:1082.
- Paroxetine (Brisdelle) for hot flashes. Med Lett Drugs Ther 2013; 55:85.
- SD Reed et al. Lights on MsFLASH: a review of contributions. Menopause 2020; 27:473.
- D Shan et al. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. Am J Obstet Gynecol 2019; 222:564.
- H Joffe et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol 2010; 202:171.
- RA Leon-Ferre et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectrum 2020; 4:pkz088.
- Oxybutynin for hot flashes in women with breast cancer. Med Lett Drugs Ther 2019; 61:30.
- PP Guo et al. Complementary and alternative medicine for natural and treatment-induced vasomotor symptoms: an overview of systematic reviews and meta-analyses. Complement Ther Clin Pract 2019; 36:181.
- OH Franco et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA 2016; 315:2554.
- S Dodin et al. The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metab 2005; 90:1390.
- M Ghazanfarpour et al. Effects of flaxseed and Hypericum perforatum on hot flash, vaginal atrophy and estrogen-dependent cancers in menopausal women: a systematic review and meta-analysis. Avicenna J Phytomed 2016; 6:273.
- K Winther et al. Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. Climacteric 2005; 8:162.
- SD Reed et al. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause 2008; 15:51.
- AC Brown et al. Liver toxicity related to herbs and dietary supplements: online table of case reports. Part 2 of 5 series. Food Chem Toxicol 2017; 107:472.
- NAMS. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015; 22:1155.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.